Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically ...
Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developments for ...
Currently, a Phase III study of ivonescimab monotherapy versus pembrolizumab monotherapy ... regimen as first-line treatment for pancreatic cancer. Overall, ivonescimab is engaged in over ...